+14.47%
Today
Loading 1D prices…
Company profile
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Sector
Health Care
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Exchange
Nasdaq
Display currency
USD
Location
ORLANDO, FL, United States
Fiscal year end
0131
CIK
1676047
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SPAISafe Pro Group Inc. Common Stock | $91.4M | $606.7K | -2360.84% | -$0.85 | -1.09% | Buy |
| LAKELakeland Industries Inc. Common Stock | $100.1M | $192.6M | -13.14% | -$2.63 | +3.01% | Buy |
| COCHEnvoy Medical Inc. Class A Common Stock | $57.1M | $241K | -9857.26% | -$1.23 | +4.23% | Buy |
| CNXUConexeu Sciences Inc. Common Stock | $125.8M | $0.00 | — | -$0.1876 | +5.65% | Buy |
| APTAlpha Pro Tech Ltd. Common Stock | $53M | $59.1M | +5.92% | $0.33 | -0.57% | Unrated |